240 related articles for article (PubMed ID: 30402978)
1. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
Kikuchi K; Nozawa K; Yamazaki N; Nakai Y; Higashiyama A; Asano M; Fujiwara Y; Kanda S; Ohe Y; Takashima A; Boku N; Inoue A; Takahashi M; Mori T; Taguchi O; Inoue Y; Mizutani H
J Dermatol; 2019 Jan; 46(1):18-25. PubMed ID: 30402978
[TBL] [Abstract][Full Text] [Related]
2. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.
Bierbrier R; D'Aguanno K; Oliel S; Zeng Y; Esfahani K; Pehr K
J Cutan Med Surg; 2023 Nov; 27(6):614-620. PubMed ID: 37942582
[TBL] [Abstract][Full Text] [Related]
3. Severe EGFR inhibitor-induced acneiform eruption responding to dapsone.
Beshay A; Petersen M; Rhoads JLW
Dermatol Online J; 2021 Jul; 27(7):. PubMed ID: 34391331
[TBL] [Abstract][Full Text] [Related]
4. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
[TBL] [Abstract][Full Text] [Related]
5. Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part).
Kikuchi K; Yamazaki N; Nozawa K; Fukuda H; Shibata T; Machida R; Hamaguchi T; Takashima A; Shoji H; Boku N; Takatsuka S; Takenouchi T; Nishina T; Yoshikawa S; Takahashi M; Hasegawa A; Kawazoe A; Masuishi T; Mizutani H; Kiyohara Y
Support Care Cancer; 2022 May; 30(5):4497-4504. PubMed ID: 35113224
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
7. [Acneiform eruption from epidermal growth factor receptor inhibitors].
Martínez de Lagrán Z; Ratón JA; Lasa O; Acebo E; Díaz-Pérez JL
Actas Dermosifiliogr; 2005 Sep; 96(7):450-4. PubMed ID: 16476273
[TBL] [Abstract][Full Text] [Related]
8. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
9. [Acneiform eruptions induced by cetuximab].
Walon L; Gilbeau C; Lachapelle JM
Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
[TBL] [Abstract][Full Text] [Related]
10. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
11. CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.
Jarząbek T; Rucińska M; Rogowski W; Lewandowska M; Tujakowski J; Habib M; Kowalczyk A; Byszek A; Dziadziuszko R; Nawrocki S
Mol Diagn Ther; 2015 Apr; 19(2):79-89. PubMed ID: 25721848
[TBL] [Abstract][Full Text] [Related]
12. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
13. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Chiang TY; Hsu HC; Jane SW; Chen SC
Support Care Cancer; 2020 Oct; 28(10):4771-4779. PubMed ID: 31974771
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors.
Bierbrier R; Lam M; Pehr K
Dermatol Ther; 2022 May; 35(5):e15412. PubMed ID: 35220635
[TBL] [Abstract][Full Text] [Related]
15. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
16. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
17. Cetuximab-induced acneiform eruption and the response to isotretinoin.
Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
[No Abstract] [Full Text] [Related]
18. Severe acneiform eruption induced by cetuximab (Erbitux).
Lee JE; Lee SJ; Lee HJ; Lee JH; Lee KH
Yonsei Med J; 2008 Oct; 49(5):851-2. PubMed ID: 18972607
[TBL] [Abstract][Full Text] [Related]
19. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
20. Rosaceiform eruption induced by cetuximab.
Fernández-Torres R; Martínez Gomez W; Cuevas Santos J; Paradela S; Fonseca Capdevila E
Eur J Dermatol; 2010; 20(3):392-3. PubMed ID: 20172848
[No Abstract] [Full Text] [Related]
[Next] [New Search]